xMD Diagnostics, Inc. specializes in molecular diagnostics tools aimed at enhancing the capabilities of pathologists, oncologists, and other healthcare professionals in diagnosing and treating cancer and serious genetic diseases. The company focuses on developing laboratory instruments and consumables that streamline the process of sample enrichment, which is essential for accurate molecular testing. By transforming traditional methods, such as manual scraping, into a highly automated workflow, xMD aims to improve both the accuracy and efficiency of diagnostic processes while significantly reducing costs.

At the core of xMD's technology is a proprietary method known as Expression Microdissection. This innovative approach allows researchers and clinicians to isolate and enrich specific cells of interest, such as malignant tumor cells, from biopsy and other specimen samples. By facilitating the procurement of high-quality cells, DNA, and RNA, Expression Microdissection serves as a critical first step in the molecular pathology workflow, enabling advanced downstream applications like PCR, genomic and proteomic analyses, and next-generation sequencing (NGS). This technology is pivotal for enhancing the precision of histology and cytology testing, ultimately contributing to better patient outcomes.

United States

xMD Diagnostics, Inc. is a molecular diagnostics tools company focused on developing a line of laboratory instruments and consumables for the rapidly growing research, biopharmaceutical and commercial clinical laboratory (CLIA) precision diagnostics markets. xMD's goal is to significantly improve pathologists', oncologists' and other physicians' ability to diagnose, monitor and treat patients with cancer and other serious genetic diseases.

xMD Diagnostics, Inc.

Company Details